Products
Services
Research Areas
COVID-19
Resources
Contact Us
Distributors
Login
Quick Order
Cart
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Services
Immunohistochemistry Services

Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting immunostaining in relation to complex human pathologies.

TCR Screening Services

Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding. Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".

Research Areas
Cell Cycle Pathways
Protein Family And Group
Infectious Disease
Contact Us
LSBio
2401 Fourth Avenue Suite 900
Seattle WA 98121
Phone:
866-819-4732 (Toll Free North America
206-374-1102 (International)
Fax:
866-206-6909 (Toll Free North America)
206-577-4565 (International)
How To Buy - Details about how to buy our products.
Orders@LSBio.com - To submit a new order.
Customer.Support@LSBio.com - To submit questions about existing orders, pricing, availability, bulk quotes, froforma invoice requests, or other billing issues.
Technical.Support@LSBio.com - To request technical information about an LSBio product or its applications
Sales@LSBio.com - To request information about fee-for-service contract IHC studies, IHC reports, distribution agreements, or general business development.
Worldwide Distributors List - To find your local distributor if you're not within the United States.
Login
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.


Fields marked with a * are required.

Login
Quick Order
Home > Coronavirus > Disease Inhibitors

Coronavirus Disease Inhibitors

LSBio offers a range of research-use-only biochemicals which have potential inhibitory action against SARS-CoV-2 infection.

Biochemicals

SARS-CoV-2 Spike (S) Protein Inhibitors

The spike (S) protein is responsible for attachment to and fusion with the host cell. For both SARS-CoV and SARS-CoV-2, the host receptor is known to be angiotensin converting enzyme 2 (ACE2) (Hoffmann, 2020). The spike protein is proteolytically cleaved into two subunits, S1 and S2. The S1 subunit binds to ACE2 presented on the host cell surface, and the S2 subunit is responsible for fusion with the host cell. Target cells include pneumocytes and macrophages expressing ACE2 in the lung, as well as ACE2-positive epithelial cells in the lung, gastrointestinal tract, and liver (cholangiocytes). The spike protein subunits are of interest as targets of vaccines; the S2 subunit is highly conserved and may be an effective pan-coronavirus target. SARS-CoV studies in monkeys immunized with full-length Spike protein showed successful protection against subsequent infection (Shang, 2020).

Camostat Mesylate

Camostat mesylate is an inhibitor of the protease TMPRSS2. This host protease is used by SARS-CoV-2 for spike protein priming, and inhibition with camostat mesylate has been shown to block SARS-CoV-2 infection in lung cell lines. (Hoffmann, 2020)

Emodin

Emodin is an anthraquinone derivative extracted from Rheum tanguticum. It has been found to inhibit the SARS-CoV ORF3a protein and also block interactions between the SARS-CoV spike protein and the ACE2 receptor. It is of interest as a potential inhibitor of SARS-CoV-2 infection. (Zhou, Y., 2020)

SARS-CoV-2 Membrane (M) Protein Inhibitors

The membrane (M) protein determines the shape of the SARS-CoV-2 viral envelope and organizes viral assembly through interaction with each additional structural protein. (Chang, 2014).

Toremifene

Toremifene is a nonsteroidal selective estrogen receptor modulator (SERM) used in the treatment of metastatic breast cancer. It has also been found to block the fusion of viral and endosomal membranes by destabilizing the viral membrane glycoprotein, and has been demonstrated to inhibit Ebola, MERS-CoV and SARS-CoV viral replication in vitro using established cell lines. It is of interest as a potential inhibitor of SARS-CoV-2 infection. (Zhou, Y., 2020)

SARS-CoV-2 Envelope (E) Protein Inhibitors

The envelope (E) protein is the smallest of the SARS-CoV-2 structural proteins, and it is incorporated into the virion envelope, though this represents only a small amount of total expressed envelope protein. A high proportion is also expressed inside the infected cell, where it is involved in viral assembly, budding, maturation, and propagation (Schoeman,2019; Chang, 2020). The E protein sequence of SARS-CoV-2 has 90% amino acid overlap with other human coronavirus envelope proteins, which may allow for the development or repurposing of pan-coronavirus antiviral drugs that target this protein.

Belachinal, Macaflavanone E & Vibsanol B Belachinal, Macaflavanone E & Vibsanol B are phytochemicals which have been shown in in silico models to potentially inhibit the activity of E protein (Gupta, M.G., 2020)

SARS-CoV-2 Papain-like Protease Inhibitors

There are two types of proteases expressed by SARS-CoV and SARS-CoV-2, the papain-like protease (PLpro, NSP3), and the CL-like protease (NSP5A & B, 3CLpro, Mpro). These proteases are responsible for cleaving the viral polyprotein and releasing nonstructural proteins (NSPs). These NSPs are vital for SARS-CoV-2 viral replication, maturation, and its overall life-cycle. In SARS-CoV, the papain-like protease (PLpro) inhibits type I interferon (IFN) by blocking IRF3 phosphorylation, which results in downstream inhibition of interferon induction and a reduction in the host’s innate immune response. This is thought to contribute to higher viral titer and leads to an increase in cell death and damage to infected and surrounding tissue (Matthews, 2014). The SARS-CoV-2 papain-like protease is thus of interest as a drug target to prevent viral replication and potentially reduce tissue damage (Báez-Santos, 2015)

Lopinavir

Lopinavir is the most powerful inhibitor of CoV protease and Saquinavir is the least powerful. As per current guidelines, Lopinavir + Ritonavir is the recommended protease inhibitor combination for the treatment of 2019-nCoV.

Mercaptopurine (6MP)

Mercaptopurine has been found to inhibit both SARS-CoV and MERS-CoV papain-like protease (PLpro), a protein necessary for viral maturation, and mercaptopurine acts as an anti-inflammatory agent by inhibiting interferon stimulation via proteases. (Zhou,Y., 2020)(Chen, X. 2009)(Cheng, KW., 2015)

Darunavir

Darunavir is a protease inhibitor. When used in combination with cobicistat it has been found to inhibit the 3CL-protease (3CLpro), thereby blocking viral replication.

Oseltamivir (Tamiflu)

Oseltamivir is a neuraminidase inhibitor, a competitive inhibitor of influenza's neuraminidase enzyme. The enzyme cleaves the sialic acid which is found on glycoproteins on the surface of human cells that helps new virions to exit the cell. The use of oseltamivir in combination ASC09 or Ritonavir is currently under clinical study for treating coronavirus infections. (Harrison, C., 2020)

Nelfinavir

Nelfinavir is an HIV-1 protease inhibitor that has been demonstrated to also suppress SARS-CoV viral replication (Yamamoto, 2004). Nelfinavir is of interest in COVID-19 antiviral drug research, as it was found to inhibit the SARS-CoV-2 papain-like protease (plPro, mPro) when tested in Vero E6 cells (Xu, 2020). It has also been shown to inhibit inflammatory cytokines in vitro and may be effective in reducing the inflammatory response and severe innate immune activation resulting from COVID-19 and other viral diseases (Xu, 2020; Wallet, 2012).

SARS-CoV-2 NSP12 Polymerase Inhibitors

NSP12 RNA-dependent RNA polymerase (RdRP, RDR, RNA replicase) is an enzyme that catalyzes the replication of RNA from an RNA template. RdRp is a crucial viral enzyme in the life cycle of RNA viruses. In all positive-strand RNA viruses including SARS-CoV and SARS-CoV-2, RdRP constitutes the central catalytic subunit of the machinery involved in RNA synthesis and catalyzes the replication and transcription of the RNA genome (te Velthuis, 2010).

Acyclovir

Acyclovir is a synthetic nucleoside analog that serves as polymerase inhibitor. Acyclovir fleximers have shown to inhibit HCov-NL63 and MERS-CoV. (Creative Biolabs, 2020)

Baloxavir marboxil

Baloxavir marboxil is a Cap-dependent endonuclease inhibitor and is used in combination with favipiravir, a nucleoside analog RdRp polymerase inhibitor, for SARS-COV-2 treatment (Harrison, C., 2020)

Favipiravir (T-705)

Favipiravir is in an RNA polymerase inhibitor used for the treatment of Influenza A and B. Although it has not shown strong activity against SARS-CoV-2 (Wang, M., 2020), it is still in trial for use in combination with other therapies. (Harrison, C., 2020)

Emtricitabine

Emtricitabine acts as a reverse transcriptase inbibitor. Although coronaviruses do not have reverse transcriptase, repurposing of these inhibitors is being explored in concert with other antivirals for treatment of COVID-19. (Harrison, C., 2020)

Tenofovir

Tenofovir acts a guanosine analog reverse transcriptase inhibitor. In combination, Emtricitabine/ Tenofovir inhibit viral RNA synthesis. These have been used in trials in combination with guanosine analogs and RNA synthesis inhibitors. (Harrison, C., 2020)

Galidesivir (BCX4430, Immucillin-A)

Galidesivir tightly binds to RdRP and is used as a polymerase inhibitor. (Elfiky A.A, 2020)

Remdesivir

Remdesivir is a broad spectrum anti-viral, developed against Ebola virus, and is being tried as anti-replicase.

Ribavirin

Ribavirin is anti-polymerase drug which binds tightly to RdRp. (Elfiky. A, 2020)

Sofosbuvir

Sofosbuvir is an anti-HCV drug which targets RdRp. (Elfiky A.A., 2020)

SARS-CoV-2 Open Reading Frame 3 (ORF3a) Inhibitors

The ORF3a protein expressed by SARS-CoV-2 has 72% sequence homology with SARS-CoV ORF3a. In SARS-CoV, the ORF3a protein activates NF-κB and the NLRP3 inflammasome by inducing TRAF3-dependent ubiquitination of p105 and ASC (Kam-Leung Siu, 2019). There is evidence that the SARS-CoV-2 virus is less effective in activating the NLRP3 inflammasome and in suppressing the antiviral response when compared to SARS-CoV. More studies are needed to fully understand how the SARS-CoV-2 ORF3a protein influences the immune and inflammatory response as it pertains to COVID-19 disease progression (Yuen, 2020; Zeng, 2004).

Tranilast

Tranilast inhibits activation of the NLRP3 inflammasome pathway, which is activated by ORF3a.


References:

  • Chang, C. K., Hou, M. H., Chang, C. F., Hsiao, C. D., & Huang, T. H. (2014). The SARS coronavirus nucleocapsid protein--forms and functions. Antiviral Research, 103, 39–50.
  • Chen, X., Chou, C. Y., & Chang, G. G. (2009). Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme. Antiviral Chemistry & Chemotherapy, 19(4), 151–156.
  • Cheng, K. W., Cheng, S. C., Chen, W. Y., Lin, M. H., Chuang, S. J., Cheng, I. H., Sun, C. Y., & Chou, C. Y. (2015). Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Research, 115, 9–16.
  • Creative Bioloabs. (2020). Acyclovir Fleximer for the Treatment of SARS-CoV-2. https://sars-cov-2.creative-biolabs.com/acyclovir-fleximer-for-the-treatment-of-sars-cov2.htm.
  • Elfiky A. A. (2020). Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sciences, 117592.
  • Gupta, M. K., Vemula, S., Donde, R., Gouda, G., Behera, L., & Vadde, R. (2020). In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel. Journal of Biomolecular Structure & Dynamics, 1–11.
  • Harrison, C. (2020, Feb 20). Coronavirus puts drug repurposing on the fast track. Nature Biotechnology. https://www.nature.com/articles/d41587-020-00003-1.
  • Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181(2), 271–280.e8.
  • Schoeman, D., & Fielding, B. C. (2019). Coronavirus envelope protein: current knowledge. Virology Journal, 16(1), 69.
  • Shang, W., Yang, Y., Rao, Y., & Rao, X. (2020). The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. NPJ Vaccines, 5, 18.
  • Siu, K. L., Yuen, K. S., Castaño-Rodriguez, C., Ye, Z. W., Yeung, M. L., Fung, S. Y., Yuan, S., Chan, C. P., Yuen, K. Y., Enjuanes, L., & Jin, D. Y. (2019). Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 33(8), 8865–8877.
  • te Velthuis, A. J., van den Worm, S. H., Sims, A. C., Baric, R. S., Snijder, E. J., & van Hemert, M. J. (2010). Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathogens, 6(11).
  • Wallet, M. A., Reist, C. M., Williams, J. C., Appelberg, S., Guiulfo, G. L., Gardner, B., Sleasman, J. W., & Goodenow, M. M. (2012). The HIV-1 protease inhibitor nelfinavir activates PP2 and inhibits MAPK signaling in macrophages: a pathway to reduce inflammation. Journal of Leukocyte Biology, 92(4), 795–805.
  • Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research, 30(3), 269–271.
  • Xu, Z., Yao, H., Shen, J., Wu, N., Xu, Y., Lu, X., zhu. w., & Li, L.-J. (2020). Nelfinavir Is Active Against SARS-CoV-2 in Vero E6 Cells. ChemRxiv. 12039888.v1 https://doi.org/10.26434/chemrxiv.12039888.v1.
  • Yamamoto, N., Yang, R., Yoshinaka, Y., Amari, S., Nakano, T., Cinatl, J., Rabenau, H., Doerr, H. W., Hunsmann, G., Otaka, A., Tamamura, H., Fujii, N., & Yamamoto, N. (2004). HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochemical and Biophysical Research Communications, 318(3), 719–725.
  • Zeng, R., Yang, R. F., Shi, M. D., Jiang, M. R., Xie, Y. H., Ruan, H. Q., Jiang, X. S., Shi, L., Zhou, H., Zhang, L., Wu, X. D., Lin, Y., Ji, Y. Y., Xiong, L., Jin, Y., Dai, E. H., Wang, X. Y., Si, B. Y., Wang, J., Wang, H. X., … Wu, J. R. (2004). Characterization of the 3a protein of SARS-associated coronavirus in infected vero E6 cells and SARS patients. Journal of Molecular Biology, 341(1), 271–279.
  • Zhou, Y., Hou, Y., Shen, J., Huang, Y., Martin, W., & Cheng, F. (2020). Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discovery, 6, 14.

☰ Filters
No (50)
Yes (1)
Viewing 1-25 of 51 items
Lopinavir Biochemical
Select
192725-17-0
C37H48N4O5
White to off white powder / Greater than 98%
1g   $200.00; 100mg   $105.00; 5g   $704.00; 500mg   $165.00
Oseltamivir Phosphate Biochemical
Select
204255-11-8
C16H28N2O4 H3O4P
White Crystal Powder / Greater than 98%
10mg   $135.00; 100mg   $469.00; 25mg   $195.00
Ribavirin Biochemical
Select
36791-04-5
C8H12N4O5
White Crystal Powder / Greater than 98%
100mg   $125.00; 25mg   $95.00; 50mg   $105.00; 500mg   $170.00
Ribavirin Biochemical - Ribavirin Structure
Select
36791-04-5
Chemical
C8H12N4O5
White solid / Greater than 98% by NMR, TLC
100mg   $50.00; 250mg   $105.00
Ritonavir Biochemical
Select
155213-67-5
C37H48N6O5S2
White to off white powder / Greater than 98%
1g   $346.00; 100mg   $105.00; 250mg   $155.00
Sofosbuvir Biochemical
Select
1190307-88-0
C22H29FN3O9P
Yellow to off white powder / Greater than 98%
1mg   $110.00; 10mg   $215.00; 25mg   $364.00; 5mg   $140.00; 50mg   $556.00
Biochemical - Emodin Structure
Select
518-82-1
Chemical
C15H10O5
a crystalline solid / Greater than 98%
100mg   $110.00; 25mg   $40.00; 50mg   $60.00
Biochemical - E-64d Structure
Select
88321-09-9
Chemical
C17H30N2O5
a crystalline solid / Greater than 98%
10mg   $235.00; 25mg   $465.00; 5mg   $150.00
Biochemical - AS 604850: A selective, ATP-competitive inhibitor of PI3K?
Select
1187595-84-1
Chemical
44231848
C16H20N7O6PS
Pale yellow to Yellow Solid / Greater than 98% by HPLC
50mg   $535.00; 10mg   $155.00
Biochemical - AS 604850: A selective, ATP-competitive inhibitor of PI3K?
Select
1187594-09-7
Chemical
44205240
C16H17N7O2S
Off-white to White Solid / Greater than 98% by HPLC
50mg   $535.00; 10mg   $155.00
Biochemical - NVP-AEW541: A novel, potent and selective inhibitor of IGF-IR kinase
Select
1004316-88-4
Chemical
25151504
C40H53N7O5S2
Off-white to White Solid / Greater than 98% by HPLC
25mg   $640.00; 5mg   $190.00
Biochemical - Acyclovir Structure
Select
59277-89-3
Chemical
C8H11N5O3
a crystalline solid / Greater than 98%
100mg   $130.00; 50mg   $75.00; 500mg   $515.00
Biochemical - Arbidol (hydrochloride) Structure
Select
131707-23-8
Chemical
C22H25BrN2O3S • HCl
a crystalline solid / Greater than 98%
10mg   $85.00; 100mg   $370.00; 50mg   $215.00
Biochemical - BCX4430 Structure
Select
249503-25-1
Chemical
C11H15N5O3
a solid / Greater than 98%
1mg   $630.00; 500µg   $400.00
Biochemical - Darunavir Structure
Select
206361-99-1
Chemical
C27H37N3O7S
a crystalline solid / Greater than 98%
1mg   $75.00; 10mg   $320.00; 5mg   $185.00
Biochemical - Camostat (mesylate) Structure
Select
59721-29-8
Chemical
C20H22N4O5• CH3SO3H
a crystalline solid / Greater than 98%
10mg   $50.00; 25mg   $105.00; 50mg   $150.00
Biochemical
Select
159989-65-8
64142
C32H45N3O4S CH3SO3H
White powder
5mg   $75.00; 25mg   $245.00
Biochemical - Ruxolitinib Structure
Select
941678-49-5
Chemical
C17H18N6
a crystalline solid / Greater than 98%
10mg   $235.00; 25mg   $370.00; 5mg   $130.00
Biochemical - TG101348 Structure
Select
936091-26-8
Chemical
C27H36N6O3S
a crystalline solid / Greater than 98%
10mg   $180.00; 25mg   $370.00; 5mg   $115.00
Biochemical - PSI-7977 Structure
Select
1190307-88-0
Chemical
C22H29FN3O9P
a crystalline solid / Greater than 98%
1mg   $75.00; 10mg   $285.00; 5mg   $170.00
Biochemical - Saquinavir (mesylate) Structure
Select
149845-06-7
Chemical
C38H50N6O5• CH3SO3H
a crystalline solid / Greater than 98%
10mg   $70.00; 25mg   $160.00; 50mg   $270.00
Biochemical - Tranilast Structure
Select
53902-12-8
Chemical
C18H17NO5
a crystalline solid / Greater than 98%
10mg   $50.00; 5mg   $35.00; 50mg   $145.00
Biochemical - Ruxolitinib (free base) Structure
Select
941678-49-5
Chemical
C17H18N6
White to off-white solid. / Greater than 98% by HPLC
25mg   $160.00; 5mg   $75.00
Biochemical - Emodin Structure
Select
518-82-1
Chemical
C15H10O5
Orange solid. / Greater than 98%
250mg   $265.00; 50mg   $75.00
Select
53902-12-8
Chemical, Antagonist
C18H17NO5
Light-yellow to green crystalline powder / Greater than 99% by HPLC Heavy Metals: Less than 15 ppm
25mg   $235.00

Viewing 1-25 of 51 items